claim: sars-cov-2 spike protein promotes hyper-inflammatory response that can be ameliorated by spike-antagonistic peptide and fda-approved er stress and map kinase inhibitors in vitro
evidence_1: we developed an antagonistic peptide that inhibits s1-ace2 interaction and cov2-s1-induced productions of pro-inflammatory cytokines.", "here we demonstrate that 2019 sars-cov-2 spike protein subunit 1 (cov2-s1) induces high levels of nf-κb activations, production of pro- inflammatory cytokines and mild epithelial damage, in human bronchial epithelial cells.")